Skip to content

Researchers recommend larger phase of clinical trial to treat Covid-19 pneumonia with 'namilumab'

The antibody is in the last stage of trials to treat rheumatoid arthritis.

A study featured in The Lancet Respiratory Medicine journal revealed that 'namilumab, a new drug, could be used to treat patients with Covid-19 pneumonia effectively.

A team of researchers, including those of the University of Birmingham and the University of Oxford, have tested the antibody 'namilumab' in patients with Covid-19 pneumonia. The antibody is in the last stage of trials to treat rheumatoid arthritis.

This post is for paying subscribers only

Subscribe

Already have an account? Log in

Latest